Bladder Cancer Indication Withdrawn for Durvalumab Bladder Cancer Indication Withdrawn for Durvalumab

AstraZeneca is withdrawing durvalumab ' s indication for the treatment of metastatic bladder cancer after a phase 3 trial showed no survival benefit.Medscape Medical News

Source: Medscape Medical News Headlines - February 23, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news